Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
It has blended 36 important ingredients for a woman’s health, which has a mix of natural extracts, amino acids, multivitamins and minerals
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Subscribe To Our Newsletter & Stay Updated
